PDCD1 and neoplasm: Building on a hypothesis that alleviation of compensatory resistance in the TME associated with the induction of PD-1, PD-L1 and LAG-3 may improve anti-tumor response, we describe here tebotelimab anti-tumor activity and biomarkers associated with tebotelimab activity across multiple clinical settings.